E-Star BioTech Announces Dosing of First Patient in Phase 2 Clinical Trials of MANP in Resistant Hypertension
February 05, 2025 08:00 ET
|
E-Star Biotech
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, metabolic, and kidney...
E-Star BioTech Set to Initiate Phase 2 Clinical Trial of MANP in Resistant Hypertension With Support of Latest Investment
October 08, 2024 09:00 ET
|
E-Star Biotech
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, metabolic, and kidney...